top of page
WP-Tesamorelin-10mg.png

Tesamorelin

Growth hormone–releasing hormone (GHRH) analog for visceral fat reduction in HIV-associated lipodystrophy

⭐⭐⭐⭐⭐Clinically Proven Results

Clinically Proven VAT Reduction

Reduces excess visceral abdominal fat (VAT) in adults with HIV-associated lipodystrophy.

Metabolic Support

Studies report improvements in certain lipid parameters and waist circumference alongside VAT reduction.

FDA-Approved Use*

Indicated specifically to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.

*Not indicated for weight-loss management; long-term cardiovascular safety has not been established. Formulations are not substitutable.

Contraindications & Precautions

Contraindications

  • Disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation or trauma)

  • Active malignancy (prior malignancy must be inactive and treatment complete)

  • Known hypersensitivity to tesamorelin or excipients

  • Pregnancy (risk of fetal harm; no benefit during pregnancy)

Use with Caution

  • Glucose intolerance/diabetes; monitor A1c and glucose

  • Elevated IGF-1; monitor and consider discontinuation if persistent

  • Fluid retention (edema, arthralgia, carpal tunnel)

  • Injection-site reactions; rotate abdominal sites

  • Diabetic retinopathy monitoring in patients with diabetes

  • Acute critical illness — consider discontinuation

Outcomes, Dosing & Side Effects

Clinical Outcomes

  • Significant reductions in visceral adipose tissue on imaging in HIV-associated lipodystrophy

  • Improvements in select lipid measures reported in trials

  • May reduce waist circumference alongside VAT changes

  • Assess response; reevaluate continuation in non-responders

Dosing & Administration

  • EGRIFTA SV: 1.4 mg subcutaneously once daily in the abdomen (rotate sites)

  • EGRIFTA WR: 1.28 mg subcutaneously once daily; supplied as 11.6 mg/vial, reconstituted to provide 7 daily doses

  • Use the product-specific diluent and Instructions for Use; SV and WR are not substitutable

Side Effects

Common

  • Injection-site reactions (erythema, pruritus, pain, irritation, bruising)

  • Arthralgia, edema

  • Paresthesia/Carpal tunnel symptoms

  • Nausea

Serious / Monitor

  • New or recurrent malignancy risk — evaluate history carefully

  • Elevated IGF-1

  • Glucose intolerance or diabetes; consider discontinuation if no clear benefit

  • Hypersensitivity reactions

Why Choose Tesamorelin?

Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue designed to stimulate endogenous GH and increase IGF-1, targeting visceral adiposity in HIV-associated lipodystrophy with simple once-daily subcutaneous dosing.

Patient Story:
“After several months, my midsection looks noticeably slimmer and my clothes fit better. I appreciate that it’s a quick daily injection.” — Anthony R.

Mechanism of Action

  • GHRH Analogue: Stimulates pituitary release of endogenous growth hormone

  • IGF-1 Increase: Elevates IGF-1, mediating metabolic effects — monitor levels during therapy

  • Adipose Effects: Supports reduction of visceral abdominal fat (VAT)

  • Administration: Subcutaneous injection into the abdomen; rotate sites daily

This content is informational only and not a substitute for medical advice. Patients should consult a licensed provider.

bottom of page